Lung cancer (Amsterdam, Netherlands). 2021 Apr:154:51-61. doi: 10.1016/j.lungcan.2021.02.005 Q14.42025
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
德国前瞻性、观察性全国CRISP登记数据库中携带KRAS G12C突变的晚期非小细胞肺癌患者的真实世界队列(AIO-TRK-0315) 翻译改进
Martin Sebastian 1, Wilfried E E Eberhardt 2, Petra Hoffknecht 3, Martin Metzenmacher 4, Thomas Wehler 5, Konrad Kokowski 6, Jürgen Alt 7, Wolfgang Schütte 8, Reinhard Büttner 9, Lukas C Heukamp 10, Albrecht Stenzinger 11, Martina Jänicke 12, Annette Fleitz 12, Stefan Zacharias 13, Stephanie Dille 14, Annette Hipper 15, Marlen Sandberg 15, Wilko Weichert 16, Matthias Groschek 17, Eyck von der Heyde 18, Jacqueline Rauh 19, Tobias Dechow 20, Michael Thomas 21, Frank Griesinger 22; CRISP Registry Group
作者单位 +展开
作者单位
DOI: 10.1016/j.lungcan.2021.02.005 PMID: 33611226
摘要 Ai翻译
相关内容
-
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
携带KRAS G12C突变的非小细胞肺癌的真实世界预后
Wanyuan Cui et al.
Lung cancer (Amsterdam, Netherlands). 2020 Aug:146:310-317.
-
Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
纠正是:索托拉西布:KRAS G12C突变阳性非小细胞肺癌的回顾
Arnold Lee
Targeted oncology. 2023 Jan;18(1):177.
-
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation
治疗带有KRAS G12C突变的非小细胞肺癌药物sotorasib
Xinting Zheng et al.
Drugs of today (Barcelona, Spain : 1998). 2022 Apr;58(4):175-185.
-
Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
阿米拉韦:KRAS G12C突变阳性非小细胞肺癌中的疗效评估综述
Arnold Lee
Targeted oncology. 2022 Nov;17(6):727-733.
-
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
KRAS G12C突变是非小细胞肺癌培美曲塞治疗的预后不良标志物
Sehhoon Park et al.
The Korean journal of internal medicine. 2017 May;32(3):514-522.
-
[Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS®) for non-small cell lung cancer with KRAS G12C mutation]
[第一代KRAS-G12C抑制剂sotorasib(LUMAKRAS®)的药理学特征及其临床研究结果]
Hirotoshi Hoshiyama
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2023;158(5):391-398.
-
KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
NSCLC中KRAS G12C突变的小型遗传中心:sotorasib治疗反应的启示
Metin Eser et al.
Scientific reports. 2024 Nov 4;14(1):26581.
-
Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study
KRAS G12C突变晚期非小细胞肺癌的临床特征及治疗结局的真实世界研究
Oliver Illini et al.
Journal of clinical medicine. 2022 Jul 15;11(14):4098.